EISAI INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

First Posted Date
2019-07-10
Last Posted Date
2024-11-15
Lead Sponsor
Eisai Inc.
Target Recruit Count
100
Registration Number
NCT04015141
Locations
🇺🇸

Phoenix Childrens Hospital, Phoenix, Arizona, United States

🇺🇸

Center For Neurosciences, Tucson, Arizona, United States

🇺🇸

David Geffen School of Medicine at UCLA, Los Angeles, California, United States

and more 45 locations

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

First Posted Date
2019-07-05
Last Posted Date
2024-12-02
Lead Sponsor
Eisai Inc.
Target Recruit Count
301
Registration Number
NCT04008797
Locations
🇺🇸

University of California San Diego (UCSD) - Moores Cancer Center(All), La Jolla, California, United States

🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Pasadena Liver Center, Pasadena, California, United States

and more 52 locations

A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2019-07-05
Last Posted Date
2021-04-12
Lead Sponsor
Eisai Inc.
Target Recruit Count
53
Registration Number
NCT04009577
Locations
🇺🇸

Northern California Research Corp, Sacramento, California, United States

🇺🇸

PACT, Glendale, Arizona, United States

🇺🇸

Artemis Institute For Clinical Research LLC - San Diego - ClinEdge - PPDS, San Diego, California, United States

and more 12 locations

A Food-Effect Study of E7386 in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2019-06-24
Last Posted Date
2019-11-14
Lead Sponsor
Eisai Inc.
Target Recruit Count
17
Registration Number
NCT03996226
Locations
🇺🇸

PPD, Austin, Texas, United States

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2019-03-25
Last Posted Date
2024-07-09
Lead Sponsor
Eisai Inc.
Target Recruit Count
1906
Registration Number
NCT03887455
Locations
🇺🇸

Emory University Cognitive Neurology Clinic & ADRC, Atlanta, Georgia, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Ohio State University, Columbus, Ohio, United States

and more 232 locations

An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

First Posted Date
2018-12-19
Last Posted Date
2024-06-03
Lead Sponsor
Eisai Inc.
Registration Number
NCT03778424
Locations
🇵🇱

Generała Tadeusza Kościuszki 52, Kielce, Poland

🇵🇱

Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland

A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2018-09-26
Last Posted Date
2020-09-28
Lead Sponsor
Eisai Inc.
Target Recruit Count
8
Registration Number
NCT03686033
Locations
🇺🇸

Consultants in Epilepsy & Neurology, PLLC, Boise, Idaho, United States

🇺🇸

Washington University Hospital, Saint Louis, Missouri, United States

🇺🇸

Clinical Trials, Inc. and Arkansas Epilepsy Program, Little Rock, Arkansas, United States

and more 2 locations

A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

Completed
Conditions
Interventions
First Posted Date
2018-09-10
Last Posted Date
2021-01-22
Lead Sponsor
Eisai Inc.
Target Recruit Count
713
Registration Number
NCT03663114
Locations
🇯🇵

Eisai trial site 1, Osaka, Japan

🇯🇵

Eisai trial site 2, Tokyo, Japan

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

First Posted Date
2018-08-14
Last Posted Date
2018-10-17
Lead Sponsor
Eisai Inc.
Target Recruit Count
40
Registration Number
NCT03627936
Locations
🇺🇸

Worldwide Clinical Trials, San Antonio, Texas, United States

A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2018-07-27
Last Posted Date
2022-05-04
Lead Sponsor
Eisai Inc.
Target Recruit Count
6
Registration Number
NCT03603639
Locations
🇺🇸

Washington University Hospital, Saint Louis, Missouri, United States

🇺🇸

Clinical Trials, Inc. and Arkansas Epilepsy Program, Little Rock, Arkansas, United States

🇺🇸

Consultants in Epilepsy & Neurology, PLLC, Boise, Idaho, United States

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath